

**Stable Angina Guideline
Guideline Development Group (GDG) Meeting 12
10 am – 4 pm Friday 22nd October 2010
National Clinical Guidelines Centre, London W1W 5QZ**

Minutes

Present

GDG

Professor Adam Timmis	GDG Chair (Cardiologist)	AT
Dr Robert Henderson	GDG Clinical Advisor (Cardiologist)	RH
Dr Maurice Pye	Cardiologist	MP
Mr Aidan McDermott	Cardiovascular Clinician	AMD
Ms Liz Clark	Patient Member	LC
Mr Sotiris Antoniou	Clinical Pharmacist	SA
Dr Charles Peebles	Cardiac Radiologist	CP
Dr Jonathan Shribman	GP (SI Cardiology)	JS
Dr Kevin Fox	Cardiologist	KF
Ms Helen O'Leary	Clinical Nurse	HOL
Dr Leonard Jacob	GP (SI Cardiology)	LJ
Mr Christopher Blauth	Surgeon	CB
Dr Roger Till	Patient Member	RT

NCGC/NICE

Ms Ann Greenwood	NICE-Editorial Lead	AG
Dr Norma O'Flynn	NCGC Clinical Director	NOF
Dr Panos Kefalas	NCGC Project Manager	PK
Dr Sharangini Rajesh	NCGC Research Fellow	SR
Ms Elisabetta Fenu	NCGC Health Economist	EF
Mr Ben Doak	NICE - Guidelines Commissioning Manager	BD

Introduction Formalities: AT welcomed the GDG to the 12th Stable Angina (SA) guideline development group (GDG) meeting and briefed the group on the meetings' objectives.

SA declared the following item of personal pecuniary interest: Presented at HRC meeting and was sponsored by Sanofi Aventis

LC declared the following item of personal non-pecuniary interest: Will be a Lay Representative on the Scottish Computed Tomography of the Heart Trail as from Wednesday 13th October,

2010

RH declared the following item of personal pecuniary interest: Sponsored by Edwards Life Science to attend Euro PCR Valve Live meeting (11-12 October 2010)

HOL declared the following item of personal pecuniary interest: Received a travel training grant by Servier to attend a training event

MP declared the following item of personal pecuniary interest: Receipt of honoraria by AstraZeneca and Pfizer for speaking at a conference (Oct 2010)

RT declared the following item of non-personal non-pecuniary interest: Appointed as a Trustee of N.A.P.P. (National Association for Patient Participation)

The remaining GDG members declared that they were no changes in their personal specific, personal non-specific, non-personal specific or non-personal non-specific interests since the previous GDG meeting.

The meeting then proceeded by first agreeing the meetings of the previous meeting and then addressing the topics below in a sequential manner:

Review of New Evidence: SR presented the latest clinical evidence available on Nicorandil (addition of 1 study: nicorandil vs nifedipine), PCI vs CABG (addition of MASS1, MASS2, SYNTAX), Medical vs Revascularisation (addition of MASS1, MASS2).

Revision of Recommendations: The GDG considered all the evidence presented and proceeded with revising recommendations accordingly.

Agreement on Key Priorities: The GDG agreed on key priorities for implementation

Identification of Research Recommendations: The GDG agreed on research recommendations

Next steps: PK presented timelines and next steps leading to the guideline's submission for consultation.

CLOSE- Next meeting 4th of March 2011